Short-term fasting accompanying chemotherapy as a supportive therapy in gynecological cancer: protocol for a multicenter randomized controlled clinical trial

Daniela Koppold-Liebscher, Christian S Kessler, Nico Steckhan, Vanessa Bähr, Cornelia Kempter, Manfred Wischnewsky, Marisa Hübner, Barbara Kunz, Marion Paul, Stefanie Zorn, Sophia Sari, Michael Jeitler, Rainer Stange, Andreas Michalsen, Daniela Koppold-Liebscher, Christian S Kessler, Nico Steckhan, Vanessa Bähr, Cornelia Kempter, Manfred Wischnewsky, Marisa Hübner, Barbara Kunz, Marion Paul, Stefanie Zorn, Sophia Sari, Michael Jeitler, Rainer Stange, Andreas Michalsen

Abstract

Background/objectives: A few preliminary studies have documented the safety and feasibility of repeated short-term fasting in patients undergoing chemotherapy. However, there is a lack of data from larger randomized trials on the effects of short-term fasting on quality of life, reduction of side effects during chemotherapy, and a possible reduction of tumor progression. Moreover, no data is available on the effectiveness of fasting approaches compared to so-called healthy diets. We aim to investigate whether the potentially beneficial effects of short-term fasting can be confirmed in a larger randomized trial and can compare favorably to a plant-based wholefood diet.

Methods: This is a multicenter, randomized, controlled, two-armed interventional study with a parallel group assignment. One hundred fifty patients, including 120 breast cancer patients and 30 patients with ovarian cancer, are to be randomized to one of two nutritional interventions accompanying chemotherapy: (1) repeated short-term fasting with a maximum energy supply of 350-400 kcal on fasting days or (2) repeated short-term normocaloric plant-based diet with restriction of refined carbohydrates. The primary outcome is disease-related quality of life, as assessed by the functional assessment of the chronic illness therapy measurement system. Secondary outcomes include changes in the Hospital Anxiety and Depression Score and as well as frequency and severity of chemotherapy-induced side effects based on the Common Terminology Criteria of Adverse Events. Explorative analysis in a subpopulation will compare histological complete remissions in patients with neoadjuvant treatments.

Discussion/planned outcomes: Preclinical data and a small number of clinical studies suggest that repeated short-term fasting may reduce the side effects of chemotherapy, enhance quality of life, and eventually slow down tumor progression. Experimental research suggests that the effects of fasting may partly be caused by the restriction of animal protein and refined carbohydrates. This study is the first confirmatory, randomized controlled, clinical study, comparing the effects of short-term fasting to a short-term, plant-based, low-sugar diet during chemotherapy on quality of life and histological tumor remission.

Trial registration: ClinicalTrials.gov NCT03162289 . Registered on 22 May 2017.

Keywords: Breast cancer; Caloric restriction; Intermittent fasting; Ovarian cancer chemotherapy; Plant-based nutrition; Randomized controlled trial; Short-term fasting.

Conflict of interest statement

The authors declare no competing interests. The sponsors of the study are not involved in the design, interpretation, or publication of the data.

Figures

Fig. 1
Fig. 1
Study design

References

    1. Fontana L, Partridge L, Longo VD. Extending healthy life span--from yeast to humans. Science. 2010;328(5976):321–326. doi: 10.1126/science.1172539.
    1. Mair W, Dillin A. Aging and survival: the genetics of life span extension by dietary restriction. Annu Rev Biochem. 2008;77:727–754. doi: 10.1146/annurev.biochem.77.061206.171059.
    1. Antoni R, Johnston KL, Collins AL, Robertson MD. Effects of intermittent fasting on glucose and lipid metabolism. Proc Nutr Soc. 2017;76(3):361–368. doi: 10.1017/S0029665116002986.
    1. Longo VD, Mattson MP. Fasting: molecular mechanisms and clinical applications. Cell Metab. 2014;19(2):181–192. doi: 10.1016/j.cmet.2013.12.008.
    1. Michalsen A, Schneider S, Rodenbeck A, Ludtke R, Huether G, Dobos GJ. The short-term effects of fasting on the neuroendocrine system in patients with chronic pain syndromes. Nutr Neurosci. 2003;6(1):11–18. doi: 10.1080/1028415021000042811.
    1. Michalsen A, Li C, Kaiser K, Ludtke R, Meier L, Stange R, et al. In-patient treatment of fibromyalgia: a controlled nonrandomized comparison of conventional medicine versus integrative medicine including fasting therapy. Evid Based Complement Alternat Med. 2013;2013:908610. doi: 10.1155/2013/908610.
    1. Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, et al. A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 2016;15(10):2136–2146. doi: 10.1016/j.celrep.2016.05.009.
    1. Colman RJ, Anderson RM, Johnson SC, Kastman EK, Kosmatka KJ, Beasley TM, et al. Caloric restriction delays disease onset and mortality in rhesus monkeys. Science. 2009;325(5937):201–204. doi: 10.1126/science.1173635.
    1. Antunes F, Erustes AG, Costa AJ, Nascimento AC, Bincoletto C, Ureshino RP, et al. Autophagy and intermittent fasting: the connection for cancer therapy? Clinics (Sao Paulo) 2018;73(suppl 1):e814s. doi: 10.6061/clinics/2018/e814s.
    1. Dorff TB, Groshen S, Garcia A, Shah M, Tsao-Wei D, Pham H, et al. Safety and feasibility of fasting in combination with platinum-based chemotherapy. BMC Cancer. 2016;16:360. doi: 10.1186/s12885-016-2370-6.
    1. de Groot S, Vreeswijk MP, Welters MJ, Gravesteijn G, Boei JJ, Jochems A, et al. The effects of short-term fasting on tolerance to (neo) adjuvant chemotherapy in HER2-negative breast cancer patients: a randomized pilot study. BMC Cancer. 2015;15:652. doi: 10.1186/s12885-015-1663-5.
    1. Bauersfeld SP, Kessler CS, Wischnewsky M, Jaensch A, Steckhan N, Stange R, et al. The effects of short-term fasting on quality of life and tolerance to chemotherapy in patients with breast and ovarian cancer: a randomized cross-over pilot study. BMC Cancer. 2018;18(1):476. doi: 10.1186/s12885-018-4353-2.
    1. Chan A, Abdullah MM, Ishak W, Ong-Cornel AB, Villalon AH, Kanesvaran R. Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: a consensus statement. J Glob Oncol. 2017;3(6):801–813. doi: 10.1200/JGO.2016.005728.
    1. Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356–1367. doi: 10.1056/NEJMra1515442.
    1. Cave J, Paschalis A, Huang CY, West M, Copson E, Jack S, et al. A systematic review of the safety and efficacy of aerobic exercise during cytotoxic chemotherapy treatment. Support Care Cancer. 2018;26(10):3337–3351. doi: 10.1007/s00520-018-4295-x.
    1. Duregon F, Vendramin B, Bullo V, Gobbo S, Cugusi L, Di Blasio A, et al. Effects of exercise on cancer patients suffering chemotherapy-induced peripheral neuropathy undergoing treatment: a systematic review. Crit Rev Oncol Hematol. 2018;121:90–100. doi: 10.1016/j.critrevonc.2017.11.002.
    1. Nurgali K, Jagoe RT, Abalo R. Editorial: Adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae? Front Pharmacol. 2018;9:245. doi: 10.3389/fphar.2018.00245.
    1. Lee C, Raffaghello L, Brandhorst S, Safdie FM, Bianchi G, Martin-Montalvo A, et al. Fasting cycles retard growth of tumors and sensitize a range of cancer cell types to chemotherapy. Sci Transl Med. 2012;4(124):124ra27. doi: 10.1126/scitranslmed.3003293.
    1. Raffaghello L, Lee C, Safdie FM, Wei M, Madia F, Bianchi G, et al. Starvation-dependent differential stress resistance protects normal but not cancer cells against high-dose chemotherapy. Proc Natl Acad Sci U S A. 2008;105(24):8215–8220. doi: 10.1073/pnas.0708100105.
    1. Lee C, Longo VD. Fasting vs dietary restriction in cellular protection and cancer treatment: from model organisms to patients. Oncogene. 2011;30(30):3305–3316. doi: 10.1038/onc.2011.91.
    1. Lee C, Safdie FM, Raffaghello L, Wei M, Madia F, Parrella E, et al. Reduced levels of IGF-I mediate differential protection of normal and cancer cells in response to fasting and improve chemotherapeutic index. Cancer Res. 2010;70(4):1564–1572. doi: 10.1158/0008-5472.CAN-09-3228.
    1. Nencioni A, Caffa I, Cortellino S, Longo VD. Fasting and cancer: molecular mechanisms and clinical application. Nat Rev Cancer. 2018;18(11):707–719. doi: 10.1038/s41568-018-0061-0.
    1. Michalsen A, Kuhlmann MK, Ludtke R, Backer M, Langhorst J, Dobos GJ. Prolonged fasting in patients with chronic pain syndromes leads to late mood-enhancement not related to weight loss and fasting-induced leptin depletion. Nutr Neurosci. 2006;9(5–6):195–200. doi: 10.1080/10284150600929656.
    1. Bruera E. ABC of palliative care. Anorexia, cachexia, and nutrition. BMJ. 1997;315(7117):1219–1222. doi: 10.1136/bmj.315.7117.1219.
    1. Shike M. Nutrition therapy for the cancer patient. Hematol Oncol Clin North Am. 1996;10(1):221–234. doi: 10.1016/S0889-8588(05)70336-1.
    1. O’Flanagan CH, Smith LA, McDonell SB, Hursting SD. When less may be more: calorie restriction and response to cancer therapy. BMC Med. 2017;15(1):106. doi: 10.1186/s12916-017-0873-x.
    1. Safdie FM, Dorff T, Quinn D, Fontana L, Wei M, Lee C, et al. Fasting and cancer treatment in humans: a case series report. Aging (Albany NY) 2009;1(12):988–1007. doi: 10.18632/aging.100114.
    1. Schupp M, Chen F, Briggs ER, Rao S, Pelzmann HJ, Pessentheiner AR, et al. Metabolite and transcriptome analysis during fasting suggest a role for the p53-Ddit4 axis in major metabolic tissues. BMC Genomics. 2013;14:758. doi: 10.1186/1471-2164-14-758.
    1. Zeng X, Yan T, Schupp JE, Seo Y, Kinsella TJ. DNA mismatch repair initiates 6-thioguanine--induced autophagy through p53 activation in human tumor cells. Clin Cancer Res. 2007;13(4):1315–1321. doi: 10.1158/1078-0432.CCR-06-1517.
    1. Colbert LH, Westerlind KC, Perkins SN, Haines DC, Berrigan D, Donehower LA, et al. Exercise effects on tumorigenesis in a p53-deficient mouse model of breast cancer. Med Sci Sports Exerc. 2009;41(8):1597–1605. doi: 10.1249/MSS.0b013e31819f1f05.
    1. Sonntag WE, Lynch CD, Cefalu WT, Ingram RL, Bennett SA, Thornton PL, et al. Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: inferences from moderate caloric-restricted animals. J Gerontol A Biol Sci Med Sci. 1999;54(12):B521–B538. doi: 10.1093/gerona/54.12.B521.
    1. Spindler SR. Caloric restriction: from soup to nuts. Ageing Res Rev. 2010;9(3):324–353. doi: 10.1016/j.arr.2009.10.003.
    1. Mauro CR, Tao M, Yu P, Trevino-Villerreal JH, Longchamp A, Kristal BS, et al. Preoperative dietary restriction reduces intimal hyperplasia and protects from ischemia-reperfusion injury. J Vasc Surg. 2016;63(2):500–9.e1. doi: 10.1016/j.jvs.2014.07.004.
    1. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjonneland A, et al. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. Br J Cancer. 2008;98(9):1574–1581. doi: 10.1038/sj.bjc.6604331.
    1. Robertson LT, Trevino-Villarreal JH, Mejia P, Grondin Y, Harputlugil E, Hine C, et al. Protein and calorie restriction contribute additively to protection from renal ischemia reperfusion injury partly via leptin reduction in male mice. J Nutr. 2015;145(8):1717–1727. doi: 10.3945/jn.114.199380.
    1. RStudio SS. 2018. Accessed 11 Sept 2020.
    1. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, et al. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med. 2008;358(16):1663–1671. doi: 10.1056/NEJMoa0707056.
    1. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21(6):976–983. doi: 10.1200/JCO.2003.02.063.
    1. Boyd LR, Muggia FM. Carboplatin/paclitaxel induction in ovarian cancer: the finer points. Oncology (Williston Park) 2018;32(8):418–420.
    1. Lee MX, Tan DS. Weekly versus 3-weekly paclitaxel in combination with carboplatin in advanced ovarian cancer: which is the optimal adjuvant chemotherapy regimen? J Gynecol Oncol. 2018;29(6):e96. doi: 10.3802/jgo.2018.29.e96.
    1. Fastenakademie DD. 2016. Accessed 11 Sept 2020.
    1. Gesundheitsberatung UU. 2019. Accessed 11 Sept 2020.
    1. Michalsen A, Li C. Fasting therapy for treating and preventing disease - current state of evidence. Forsch Komplementmed. 2013;20(6):444–453. doi: 10.1159/000357765.
    1. Wilhelmi de Toledo F, Grundler F, Bergouignan A, Drinda S, Michalsen A. Safety, health improvement and well-being during a 4 to 21-day fasting period in an observational study including 1422 subjects. PLoS One. 2019;14(1):e0209353. doi: 10.1371/journal.pone.0209353.
    1. Li C, Ostermann T, Hardt M, Ludtke R, Broecker-Preuss M, Dobos G, et al. Metabolic and psychological response to 7-day fasting in obese patients with and without metabolic syndrome. Forsch Komplementmed. 2013;20(6):413–420. doi: 10.1159/000353672.
    1. Wilhelmi de Toledo F, Buchinger A, Burggrabe H, Holz G, Kuhn C, Lischka E, et al. Fasting therapy - an expert panel update of the 2002 consensus guidelines. Forsch Komplementmed. 2013;20(6):434–443. doi: 10.1159/000357602.
    1. Stange R, Pflugbeil C, Michalsen A, Uehleke B. Therapeutic fasting in patients with metabolic syndrome and impaired insulin resistance. Forsch Komplementmed. 2013;20(6):421–426. doi: 10.1159/000357875.
    1. Bosmann S, Paul A. Vegetarisch vollwertig kochen. NATUR UND MEDIZIN KVC Verlag; 2015.
    1. Krebsgesellschaft eVD. 2018. Accessed 11 Sept 2020.
    1. . 2010. Accessed 11 Sept 2020.
    1. Tofthagen CS, McMillan SC, Kip KE. Development and psychometric evaluation of the chemotherapy-induced peripheral neuropathy assessment tool. Cancer Nurs. 2011;34(4):E10–E20. doi: 10.1097/NCC.0b013e31820251de.
    1. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13(3):176–181. doi: 10.1016/S1053-4296(03)00031-6.
    1. Wong LP. Focus group discussion: a tool for health and medical research. Singap Med J. 2008;49(3):256–260.
    1. Schunemann HJ, Akl EA, Guyatt GH. Interpreting the results of patient reported outcome measures in clinical trials: the clinician’s perspective. Health Qual Life Outcomes. 2006;4:62. doi: 10.1186/1477-7525-4-62.
    1. Jongbloed F, Saat TC, Verweij M, Payan-Gomez C, Hoeijmakers JH, van den Engel S, et al. A signature of renal stress resistance induced by short-term dietary restriction, fasting, and protein restriction. Sci Rep. 2017;7:40901. doi: 10.1038/srep40901.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe